肾上腺皮质癌（ACC）是一种罕见且高度异质性的疾病，由于诊断和治疗面临巨大挑战，预后极差。强调精准医学的重要性，人们越来越需要全面的基因组资源以及完善的实验模型来制定个性化的治疗策略。我们推出了 ACC_CellMinerCDB，这是一个实质性基因组和药物敏感性数据库（可在 https://discover.nci.nih.gov/acc_cellminercdb 获取），包含 ACC 细胞系、患者来源的异种移植物、手术样本，以及对 2,400 多种药物检查的反应NCI 和 NCATS。该数据库揭示了 ACC 细胞系和手术样本之间共享的基因组通路，从而验证了细胞系作为研究模型的有效性。它还允许探索相关的治疗标志物，如 MDR-1、SOAT1、MGMT、MMR 和 SLFN11，并引入重新利用替莫唑胺等药物用于 ACC 治疗的潜力。 ACC_CellMinerCDB 为探索更大的临床前 ACC 模型提供了基础。

Adrenocortical carcinoma (ACC) is a rare and highly heterogeneous disease with a notably poor prognosis due to significant challenges in diagnosis and treatment. Emphasising on the importance of precision medicine, there is an increasing need for comprehensive genomic resources alongside well-developed experimental models to devise personalized therapeutic strategies. We present ACC_CellMinerCDB, a substantive genomic and drug sensitivity database (available at https://discover.nci.nih.gov/acc_cellminercdb) comprising ACC cell lines, patient-derived xenografts, surgical samples, combined with responses to over 2,400 drugs examined by NCI and NCATS. This database exposes shared genomic pathways among ACC cell lines and surgical samples, thus authenticating the cell lines as research models. It also allows exploration of pertinent treatment markers such as MDR-1, SOAT1, MGMT, MMR and SLFN11, and introduces the potential to repurpose agents like temozolomide for ACC therapy. ACC_CellMinerCDB provides the foundation for exploring larger preclinical ACC models.